CTOs on the Move

Tobii Dynavox

www.tobiidynavox.com

 
Tobii Dynavox, a wholly owned subsidiary of Tobii AB (publ), is the leading global provider of eye tracking enabled and touch-based augmented and alternative communication (AAC) devices as well as symbol-based products for individuals with special needs.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Pentax Medical

PENTAX Medical is a division of Hoya Group. Its mission is to improve the standard of patient care and quality of healthcare delivery by providing the best endoscopic products and services with a focus on QUALITY, CLINICALLY RELEVANT INNOVATION, and SIMPLICITY.   Through leading-edge R&D and manufacturing, PENTAX Medical provides endoscopic imaging devices and solutions to the global medical community. Headquartered in Japan, PENTAX Medical has a worldwide focus and presence with R&D, regional sales, service, and in-country facilities around the globe.   PENTAX Medical employees represent the diverse countries where we do business, allowing us to provide innovative solutions tailored to meet local needs.

Sroufe Healthcare Products

Sroufe Healthcare Products is a Ligonier, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Heartland Medical Sales and Services, L.L.C

Heartland Medical Sales and Services, L.L.C is a Louisville, KY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

RefleXion Medical

RefleXion Medical is on a mission to create a new cancer treatment modality through biological guidance.

Motif Neurotech

Motif Neurotech is a clinical-stage company leading the development of minimally invasive neuromodulation therapeutics for mental health. The company`s lead product, for treatment resistant depression (TRD), is a miniature implant that is designed to treat TRD by increasing activity in the prefrontal cortex. Studies over 20 years show stimulation of the pre-frontal cortex effectively treats treatment resistant depression without the side effects of anti-depressants. However, existing brain stimulation treatments like transcranial magnetic stimulation (TMS) can be expensive and challenging for patients to access, with daily treatments required for six weeks that may need to be repeated. Human and large animal studies show Motif`s prototype stimulates target brain areas like TMS, and the company is preparing to begin clinical trials of their first chronic implants in 2025. Motif`s implant is enabled by patent-pending wireless magnetoelectric power transfer developed at Rice University. Motif`s founders and key team members are clinical, medical device and academic experts with over 5,000 surgical procedures and decades of medical device experience.